Severe Hyponatremia in a Patient with Mantle Cell Lymphoma Treated with Bortezomib: A Case Report and Review of the LiteratureBrodmann S. · Klaas E.G. · Cathomas R. · Girardi V. · von Moos R.
aAbteilung Onkologie/Hämatologie, Departement Innere Medizin, bInstitut für Spitalpharmazie, Departement Institute, Kantonsspital Graubünden, Chur cNephrologie/Dialyse, Medizinische Klinik, Kantonsspital Winterthur, Switzerland
Background: Hyponatremia is a known complication of cytotoxic treatment. We observed this side effect in a patient treated with bortezomib. This paper gives an overview of the literature on antineoplastic agents that have been associated with hyponatremia. Case Report: A 77-year-old female patient with mantle cell lymphoma was admitted with rapidly progressive ataxia, slurred speech, and confusion. 43 days earlier, a second-line treatment with the proteasome inhibitor bortezomib had been started. Neurological examination revealed no focal deficits. Laboratory evaluation showed a combined electrolyte disorder with severe hyponatremia (sodium 112 mmol/l). Results: A syndrome of inappropriate secretion of antidiuretic hormone (SIADH) was diagnosed, and bortezomib was identified as its cause. The drug was consecutively stopped. CT scan showed a complete remission (CR). Since, the patient has remained in a CR without further tumor-specific treatment. Conclusion: Hyponatremia may be a side effect of treatment with bortezomib and a number of other antineoplastic agents. Because of limited data available, accurate incidences of this complication are not known.
|Direct payment||This item at the regular price: USD 33.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00